Marshall Wace LLP lessened its stake in shares of Catalent Inc (NYSE:CTLT) by 81.5% in the first quarter, according to its most recent Form 13F filing with the SEC. The fund owned 33,511 shares of the company’s stock after selling 147,959 shares during the period. Marshall Wace LLP’s holdings in Catalent were worth $1,360,000 as of its most recent SEC filing.
Other hedge funds and other institutional investors also recently bought and sold shares of the company. Sageworth Trust Co bought a new stake in Catalent during the first quarter valued at approximately $32,000. Financial Gravity Wealth Inc. bought a new stake in shares of Catalent in the 1st quarter worth approximately $47,000. Bremer Bank National Association bought a new stake in shares of Catalent in the 1st quarter worth approximately $49,000. Bremer Trust National Association bought a new stake in shares of Catalent in the 4th quarter worth approximately $54,000. Finally, Zions Bancorporation N.A. bought a new stake in shares of Catalent in the 1st quarter worth approximately $61,000. Institutional investors and hedge funds own 96.85% of the company’s stock.
A number of research firms recently commented on CTLT. Morgan Stanley lowered shares of GasLog Partners LP Unit from an “overweight” rating to an “equal weight” rating and lowered their price target for the company from $23.00 to $18.00 in a report on Tuesday, April 16th. UBS Group reduced their price objective on shares of Spotify from $182.00 to $180.00 and set a “buy” rating on the stock in a research report on Tuesday, April 16th. ValuEngine raised shares of ZTE CORP/ADR from a “hold” rating to a “buy” rating in a research report on Monday, April 15th. Jefferies Financial Group reissued a “buy” rating on shares of Linde in a research report on Friday, June 21st. Finally, Zacks Investment Research raised shares of DLH from a “sell” rating to a “hold” rating in a research report on Tuesday, July 9th. Nine analysts have rated the stock with a buy rating, The company currently has a consensus rating of “Buy” and a consensus target price of $53.71.
Catalent stock traded up $0.53 during mid-day trading on Thursday, reaching $54.29. The stock had a trading volume of 581,550 shares, compared to its average volume of 845,208. The company has a debt-to-equity ratio of 1.31, a current ratio of 2.18 and a quick ratio of 1.71. The firm has a market cap of $7.83 billion, a P/E ratio of 34.14, a price-to-earnings-growth ratio of 2.63 and a beta of 1.64. The company’s 50-day moving average price is $51.57. Catalent Inc has a one year low of $29.23 and a one year high of $55.98.
Catalent (NYSE:CTLT) last posted its earnings results on Tuesday, May 7th. The company reported $0.49 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.42 by $0.07. Catalent had a net margin of 6.01% and a return on equity of 16.78%. The business had revenue of $617.50 million for the quarter, compared to analysts’ expectations of $644.88 million. During the same quarter in the prior year, the business earned $0.41 EPS. The business’s revenue for the quarter was down 1.7% compared to the same quarter last year. On average, analysts forecast that Catalent Inc will post 1.71 EPS for the current year.
Catalent Company Profile
Catalent, Inc provides delivery technologies and development solutions for drugs, biologics, and consumer and animal health products worldwide. It operates through four segments: Softgel Technologies, Biologics and Specialty Drug Delivery, Oral Drug Delivery, and Clinical Supply Services. The Softgel Technologies segment formulates, develops, and manufactures prescription and consumer soft capsules for use in a range of customer products, such as prescription drugs, over-the-counter medications, dietary supplements, unit-dose cosmetics, and animal health medicinal preparations.
Read More: Bollinger Bands
Receive News & Ratings for Catalent Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalent and related companies with MarketBeat.com's FREE daily email newsletter.